ArticleAnnals of medicine2022
Article in Annals of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 48 citations in OpenAlex.
- The NLRP3 inflammasome in gastrointestinal malignancies: molecular mechanisms, regulatory networks, and therapeutic opportunities.Journal of translational medicine · 2026Review
- Esophageal cancer: from pathogenesis to precision therapies.Signal transduction and targeted therapy · 2026Review
- Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Role of tumor microenvironment in regulator of tumor progression and immunotherapy.Discover oncology · 2026Review
- Gut microbiota drives cancer evolution and therapy resistance.Molecular cancer · 2026Review
- Research on microbial communities in tumor microenvironments: cutting-edge dynamics and future trends from a bibliometric perspective.Frontiers in immunology · 2026Review
- Oral Microbiota and Carcinogenesis: Exploring the Systemic Impact of Oral Pathogens.Pathogens (Basel, Switzerland) · 2025Review
- Intestinal and esophageal microbiota in esophageal cancer development and treatment.Gut microbes · 2025Review
- Review
- AL137246.1 inhibits esophageal squamous cell carcinoma cisplatin resistance by suppressing the transcriptional activity of GLI2 on ABCC1.Molecular genetics and genomics : MGG · 2025Article
- Fusobacterium in the microbiome: from health to disease across the oral-gut axis and beyond.NPJ biofilms and microbiomes · 2025Review
- The immune microenvironment of pathogen-associated cancers and current clinical therapeutics.Molecular cancer · 2025Review
- Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer.The EMBO journal · 2025Article
- Intratumoral microbiota: a new force in the development and treatment of esophageal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Activation of the tumor cell-intrinsic STING pathway induced by Fusobacterium nucleatum is associated with poor prognosis in esophageal cancer patients.Esophagus : official journal of the Japan Esophageal Society · 2025Article
- Intratumoral microbiome: implications for immune modulation and innovative therapeutic strategies in cancer.Journal of biomedical science · 2025Review
- Unraveling the Role ofCancers · 2025Review
- Role of gut microbiome in pathogenesis and treatment of diseases: Multidisciplinary experts' opinion of the Asian Medical Experts Academy (AMEA).Gut microbes reports · 2025Review
- Article
- Periodontal disease and gastric and colorectal cancers: mechanisms and therapeutic perspectives.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo analyse the regulatory effect of
methodsFn infection, NLRP3 expression and MDSCs infiltration in ESCC tissues were detected by RNAscope and immunohistochemistry (IHC). The correlation between these three factors and the clinicopathological features and survival of ESCC patients was analysed. A coculture system of human peripheral blood monocytes (PBMCs) and ESCC cells was established to simulate the tumour microenvironment.
resultsFn infection was consistent with high NLRP3 expression and MDSCs enrichment in ESCC tissues. Moreover, the survival time of ESCC patients was significantly shortened under Fn infection, high NLRP3 expression and MDSCs enrichment. In the
conclusionsFn infection can induce high expression of NLRP3 in ESCC, lead to MDSCs enrichment, weaken the body's antitumour immunity, and lead to CDDP treatment resistance. The effective elimination of Fn and the inhibition of MDSCs enrichment may provide new strategies and treatments for ESCC.HighlightsThe survival of ESCC patients with Fn infection, high NLRP3 expression and MDSCs enrichment was significantly shortened.Fn infection could cause CDDP resistance in ESCC.Fn could induce the enrichment of MDSCs in the tumour microenvironment by activating NLRP3 in ESCC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.